Brief: Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
25/03/2025 11:33
March 25 (Reuters) - Palatin Technologies Inc PTN.A: PALATIN'S ORAL MC4R AGONIST PL7737 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR OBESITY DUE TO LEPTIN RECEPTOR DEFICIENCY PALATIN TECHNOLOGIES INC - PLANS IND SUBMISSION FOR PL7737 IN 4Q25 PALATIN TECHNOLOGIES INC - EXPECTS CLINICAL DATA FOR PL7737 IN 1H26 Source text: ID:nPnch98dka Further company coverage: PTN.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity